sur Biophytis (EPA:ALBPS)
Biophytis Announces Strategic Partnerships and Financial Results for H1 2025
Biophytis has reported its financial results for the first half of 2025, highlighting strategic developments aimed at advancing its therapeutic programs. CEO Stanislas Veillet underscored the signing of a memorandum with Asian partners to launch the first Phase 3 clinical trial for sarcopenia, showcasing the company's focus on transformative therapies. A new joint venture in Hong Kong will facilitate this initiative, involving an investment of up to USD 20 million.
In obesity treatment, Biophytis has received preclinical recognition for BIO101's role alongside GLP-1 therapies, further supported by EMBRAPII's financial backing for its Phase 2 trial. The company aims to modernize its drug discovery platform and is actively seeking partnerships to expand its strategic impact globally.
Financially, Biophytis reported a net loss decrease to €3.3 million. However, its cash position, at €1.2 million, remains a concern, emphasizing the need for ongoing fundraising efforts.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis